对于接受经皮冠状动脉介入治疗的老年糖尿病患者，还原型谷胱甘肽不会进一步降低造影剂诱发的肾病发生率。
Reduced glutathione does not further reduce contrast-induced nephropathy in elderly patients with diabetes receiving percutaneous coronary intervention.
作者信息
Wang Lingqing, Xu Enguo, Ren Shijia, Gu Xingjian, Zheng Jiping, Yang Jianguang
机构信息
Department of Cardiovascular Medicine, Taizhou First People's Hospital of Wenzhou Medical University, Taizhou, China.
出版信息
J Int Med Res. 2020 Nov;48(11):300060520964017. doi: 10.1177/0300060520964017.
OBJECTIVE
To investigate the preventive effect of hydration combined with reduced glutathione on contrast-induced nephropathy (CIN) after coronary intervention therapy in elderly Chinese patients with diabetes.
METHODS
Patients with diabetes aged ≥65 years, who received percutaneous coronary intervention (PCI) between 1 August 2016 and 31 December 2018, were enrolled and randomized into two groups: patients treated with hydration combined with reduced glutathione (treatment group) and patients who received hydration alone (controls). Serum creatinine and creatinine clearance levels were measured in all patients before PCI and then daily for 3 days after PCI. Occurrence of CIN (the primary endpoint) was defined as serum creatinine value 25% or 44.2 mmol/l (0.5 mg/dl) above baseline at 72 h after an exposure to contrast medium.
RESULTS
A total of 396 patients were included (treatment group, = 204; and controls, = 192). The CIN occurrence rate in the treatment and control group was 5.88% and 6.77%, respectively, with no statistically significant between-group difference.
CONCLUSION
In elderly patients with diabetes receiving PCI, the risk of CIN was not effectively lowered by hydration combined with reduced glutathione.
目的
探讨水化联合还原型谷胱甘肽对老年中国糖尿病患者冠状动脉介入治疗后对比剂肾病（CIN）的预防作用。
方法
纳入2016年8月1日至2018年12月31日期间接受经皮冠状动脉介入治疗（PCI）的≥65岁糖尿病患者，并随机分为两组：水化联合还原型谷胱甘肽治疗组和单纯水化治疗对照组。所有患者在PCI术前测定血清肌酐和肌酐清除率水平，术后连续3天每天测定。CIN（主要终点）的发生定义为在接触造影剂后72小时血清肌酐值比基线升高25%或44.2 mmol/l（0.5 mg/dl）以上。
结果
共纳入396例患者（治疗组204例；对照组192例）。治疗组和对照组的CIN发生率分别为5.88%和6.77%，组间差异无统计学意义。
结论
在接受PCI的老年糖尿病患者中，水化联合还原型谷胱甘肽不能有效降低CIN风险。
Zotero 插件